Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 670-673

  Solas, Caroline ^a   Gagnieu, Marie Claude ^b   Ravaux, Isabelle ^c   Drogoul, Marie Pierre ^d   Lafeuillade, Alain ^e   Mokhtari, Saadia ^f   Lacarelle, Bruno ^a   Simon, Nicolas ^a  

^a TIMONE HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e Hopital Chalucet Toulon   (France)

^f HÔPITAL NORD   (France)

Author keywords

Atazanavir; HIV patients; Population pharmacokinetic

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES;

EID: 57749095660     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181897bff     Document Type: Article

References (15)

1. Bristol Myers Squibb Company. Reyataz (Atazanavir Sulfate) Capsules. Summary Product Characteristics. London: Bristol-Myers Squibb; 2005.
2. Busti A, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:1732-1747.
3. Perloff E, Duan SX, Skolnik PR, et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005;33:764-770.
4. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP-glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729-1739.
5. Taburet A, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
6. Gonzalez de Requena D, Bonora S, Cavechia I, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range [abstract 60]. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 2005.
7. Solas, C, Colson P, Ravaux I, et al. Predictive factors of atazanavir response including genotypic inhibitory quotient in treatment-experienced patients [abstract I]. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 2005.
8. Rapport YP. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris, France: Médecine-Sciences, Flammarion; 2006.
9. Beal S, Sheiner LB. NONMEM User's Guide. San Francisco, CA: NONMEM Project Group, University of California San Francisco; 1991.
10. Boeckmann A, Scheiner L, Beal S. NONMEM User's Guide - Part V. San Francisco, CA: University of California San Francisco; 1994.
11. Karlsson M, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
12. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
13. Best B, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46:433-442.
14. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:3801-3808.
15. Solas C, Gagnieu MC, Lanet F, et al. Population pharmacokinetic of atazanavir in HIV-infected patient [abstract 52]. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 2005.